BZYR
Burzynski Research Institute, Inc. [BZYR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BZYR Stock Summary
In the News
BZYR Financial details
Company Rating
Neutral
Market Cap
4.55M
Income
-272.23K
Revenue
0
Book val./share
-0
Cash/share
0
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
31 May 2023
P/E
-62.97
Forward P/E
-
PEG
8.79
P/S
-
P/B
-1292.17
P/C
-
P/FCF
-18.9
Quick Ratio
0.22
Current Ratio
0.29
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0
EPS next Y
-
EPS next Q
-
EPS this Y
-5.41%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
73.68%
-
-
-
-
SMA20
-
SMA50
-40%
SMA100
-25%
Inst Own
0.02%
Inst Trans
1%
ROA
-5112%
ROE
319%
ROC
225.23%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.013-0.086
52W High
-
52W Low
-
RSI
45.23
Rel Volume
0.18
Avg Volume
5.41K
Volume
998
Perf Week
51.88%
Perf Month
-19%
Perf Quarter
-
Perf Half Y
-42.14%
-
-
-
-
Beta
1.478
-
-
Volatility
0.01%, 0.01%
Prev Close
-43.36%
Price
0.0243
Change
-6.54%
BZYR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-02-28
| Metric | History | 2019-02-28 | 2020-02-29 | 2021-02-28 | 2022-02-28 | 2023-02-28 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | 0 | 0 | 0 | 0 | 0 | |
| Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 2.76M | 1.45M | 6.31M | 3.94M | 4.86M | |
| Enterprise value | 2.76M | 1.45M | 6.31M | 3.94M | 4.86M | |
| P/E ratio | -1.69 | -0.88 | -5.24 | -4.04 | -5.31 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -5.78 | -2.73 | -16 | -12.13 | -19.49 | |
| PFCF ratio | -5.78 | -2.73 | -16 | -12.13 | -19.49 | |
| P/B Ratio | -14.79 | -9.48 | -137.63 | 3.27K | -354.31 | |
| PTB ratio | -14.79 | -9.48 | -137.63 | 3.27K | -354.31 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -1.69 | -0.88 | -4.85 | -4.03 | -5.31 | |
| EV to operating cash flow | -5.78 | -2.73 | -16 | -12.12 | -19.49 | |
| EV to free cash flow | -5.78 | -2.73 | -16 | -12.12 | -19.49 | |
| Earnings yield | -0.59 | -1.13 | -0.19 | -0.25 | -0.19 | |
| Free cash flow yield | -0.17 | -0.37 | -0.06 | -0.08 | -0.05 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 0 | 0 | 0 | 0 | 0 | |
| Current ratio | 0.11 | 0.12 | 0.02 | 1.35 | 0.12 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0.29 | 0.32 | 0.33 | 0.33 | 0.27 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.02 | 0.02 | 0.01 | 0 | 0 | |
| ROIC | 8.77 | 10.7 | 28.37 | -809.02 | 66.68 | |
| Return on tangible assets | -73.86 | -82.33 | -1.26K | -209.54 | -473.78 | |
| Graham Net | 0 | 0 | 0 | 0 | 0 | |
| Working capital | -186.65K | -152.59K | -45.84K | 1.21K | -13.73K | |
| Tangible asset value | -186.65K | -152.59K | -45.84K | 1.21K | -13.73K | |
| Net current asset value | -186.65K | -152.59K | -45.84K | 1.21K | -13.73K | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 71.5K | 80.94K | 46.66K | 16.26K | 6.29K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 8.77 | 10.71 | 26.26 | -809.83 | 66.75 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-11-30 for Q3
| Metric | History | 2022-11-30 | 2023-02-28 | 2023-05-31 | 2023-08-31 | 2023-11-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0 | 0.01 | 0 | 0 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | 0 | 0 | 0 | 0 | 0 | |
| Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 3.05M | 4.86M | 7.91M | 6.31M | 5.52M | |
| Enterprise value | 3.05M | 4.86M | 7.91M | 6.31M | 5.52M | |
| P/E ratio | -3.02 | 1.74 | -6.88 | -6.26 | -3.19 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -64.08 | -66.37 | -121.18 | -52.68 | -27.45 | |
| PFCF ratio | -64.08 | -66.37 | -121.18 | -52.68 | -27.45 | |
| P/B Ratio | -114.53 | -354.31 | -112.22 | -1.41K | -158.49 | |
| PTB ratio | -114.53 | -354.31 | -112.22 | -1.41K | -158.49 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -12.06 | -22.51 | -27.53 | -25.02 | -12.75 | |
| EV to operating cash flow | -64.04 | -66.36 | -121.17 | -52.67 | -27.45 | |
| EV to free cash flow | -64.04 | -66.36 | -121.17 | -52.67 | -27.45 | |
| Earnings yield | -0.08 | 0.14 | -0.04 | -0.04 | -0.08 | |
| Free cash flow yield | -0.02 | -0.02 | -0.01 | -0.02 | -0.04 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 0.01 | 0 | 0 | 0.01 | 0 | |
| Current ratio | 0.06 | 0.12 | 0.01 | 0.29 | 0.03 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0.19 | 0.34 | 0.23 | 0.48 | 0.46 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 0 | 0.01 | 0 | 0 | |
| ROIC | 9.48 | -51.02 | 4.07 | 56.27 | 12.43 | |
| Return on tangible assets | -140.98 | 362.1 | -338.92 | -140.29 | -427.46 | |
| Graham Net | 0 | 0 | 0 | 0 | 0 | |
| Working capital | -26.63K | -13.73K | -70.52K | -4.48K | -34.83K | |
| Tangible asset value | -26.63K | -13.73K | -70.52K | -4.48K | -34.83K | |
| Net current asset value | -26.63K | -13.73K | -70.52K | -4.48K | -34.83K | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 9.29K | 14.61K | 17.66K | 11.38K | 10K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 9.49 | -51.02 | 4.08 | 56.32 | 12.43 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
BZYR Frequently Asked Questions
What is Burzynski Research Institute, Inc. stock symbol ?
Burzynski Research Institute, Inc. is a US stock , located in Houston of Tx and trading under the symbol BZYR
What is Burzynski Research Institute, Inc. stock quote today ?
Burzynski Research Institute, Inc. stock price is $0.0243 today.
Is Burzynski Research Institute, Inc. stock public?
Yes, Burzynski Research Institute, Inc. is a publicly traded company.
Company Profile
- Volume Average 5.41K
- Market Capitalization 4.55M
- CEO Dr. Stanislaw R. Burzynski M.D., Ph.D.
- Headquarters Houston,TX,US
- IPO Date 1997-01-02
-
Website
https://www.burzynskiclinic.com 
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to treat cancer. The company is also involved in the production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas.
